Compare GORO & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GORO | MDXH |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 183.4M |
| IPO Year | N/A | 2021 |
| Metric | GORO | MDXH |
|---|---|---|
| Price | $1.60 | $3.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.75 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 11.7M | 158.9K |
| Earning Date | 11-04-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $61,430,000.00 | ★ $103,069,000.00 |
| Revenue This Year | $8.76 | $23.34 |
| Revenue Next Year | $85.95 | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $0.29 | $1.35 |
| 52 Week High | $1.87 | $5.33 |
| Indicator | GORO | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 65.74 | 50.58 |
| Support Level | $0.95 | $3.56 |
| Resistance Level | $1.87 | $4.34 |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 71.37 | 47.01 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.